Steve Perry, former frontman of rock band Journey and one-time Larkspur resident, is auctioning off a rare collection of ...
Arcus Biosciences Inc. and partner Gilead Sciences Inc. are scrapping phase III work with anti-TIGIT antibody domvanalimab ...
Investor's Business Daily on MSN
Why Arcus Biosciences just reversed its 287% eight-month winning streak
Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...
Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...
Dec 12 () - Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their ...
After his sinister role on The Handmaid's Tale, Josh Charles is switching gears to Fox's upcoming small town show 'Best ...
Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...
Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer ...
Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback